HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on BriaCell Therapeutics (NASDAQ:BCTX) and maintained the price target at $18.
May 24, 2024 | 11:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on BriaCell Therapeutics and maintained the price target at $18.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100